MediciNova's Ibudilast Shows Promise for Brain Metastasis Treatment in New CNIO Research
核心洞察
Researchers at the Spanish National Cancer Research Centre (搜索) identified macrophage migration inhibitory factor (搜索) (MIF (搜索))-mediated reprogramming of CD74-positive microglia and macrophages as a central vulnerability in brain metastasis (搜索).
The study published in Cancer Research demonstrates that MediciNova's ibudilast can effectively block MIF (搜索)-CD74 signaling and suppress brain metastasis (搜索) growth in preclinical models.
Brain metastases develop in up to 30% of patients with advanced solid tumors and represent a significant unmet medical need with limited treatment options.
A groundbreaking study published in Cancer Research has identified a novel therapeutic target for brain metastasis (搜索), revealing how MediciNova's investigational drug ibudilast (MN-166) could potentially address one of oncology's most challenging frontiers. The research, conducted by scientists at the Spanish National Cancer Research Centre (搜索) (CNIO (搜索)), demonstrates that targeting the MIF (搜索)-CD74 signaling pathway may offer new hope for patients with brain metastases.
Novel Mechanism Discovered in Brain Metastasis
The CNIO (搜索) research team, led by Manuel Valiente PhD, head of the Brain Metastasis (搜索) group, discovered that tumor-derived macrophage migration inhibitory factor (搜索) (MIF (搜索)) fundamentally alters the functional state of microglia and infiltrating macrophages in the brain. This process converts these immune cells from a potentially protective role into a pro-metastatic one, creating an environment that promotes cancer spread to the brain.
"Brain metastases develop in up to 30% of patients with advanced solid tumors, most commonly arising from lung cancer (搜索), breast cancer (搜索), melanoma (搜索), and colorectal cancer (搜索), and remain an area of substantial unmet medical need," explained Dr. Valiente. The researcher emphasized that despite recent advances in systemic therapies, patients with brain metastases have historically been excluded from many clinical trials, limiting progress in developing targeted treatments.
Ibudilast Demonstrates Therapeutic Potential
The study demonstrates that ibudilast can effectively block MIF (搜索)-CD74 signaling, reverse pro-metastatic immune reprogramming, and suppress brain metastasis (搜索) growth in preclinical systems. In multiple experimental models and fresh patient-derived brain metastasis samples, inhibition of the MIF-CD74 signaling axis significantly reduced metastatic progression.
Importantly, the investigators identified secreted MIF (搜索) as a candidate liquid biopsy biomarker detectable in cerebrospinal fluid, supporting a translational, biomarker-guided clinical strategy. Transcriptomic analyses also defined predictive biomarker signatures associated with treatment response, reinforcing the potential for patient stratification in future clinical studies.
Clinical Translation Strategy
Dr. Kazuko Matsuda, MediciNova's Chief Medical Officer, highlighted the significance of these findings: "Brain metastasis (搜索) represents one of the most urgent and challenging frontiers in oncology. The publication of this work in Cancer Research provides strong mechanistic and translational rationale to pursue biomarker-driven clinical strategies."
MediciNova holds granted patents covering MN-166 for preventing and minimizing cancer metastasis across multiple solid tumor types, including pancreatic, lung, breast, colorectal and ovarian cancers, as well as melanoma (搜索). The company plans to collaborate with Dr. Valiente and CNIO (搜索) on future clinical research aimed at patients with solid tumors having brain metastases.
Broader Therapeutic Pipeline
MediciNova's lead asset, MN-166 (ibudilast), is currently in Phase 3 trials for amyotrophic lateral sclerosis (搜索) (ALS) and degenerative cervical myelopathy (搜索) (DCM), and is Phase 3-ready for progressive multiple sclerosis (搜索) (MS). The drug is also being evaluated in Phase 2 trials for Long COVID (搜索) and substance dependence, demonstrating its potential across multiple therapeutic areas.
The research findings suggest that by focusing on brain-specific immune-microenvironment interactions rather than tumor-intrinsic alterations alone, this therapeutic approach may be applicable across multiple primary tumor types, potentially offering a broad-spectrum solution for brain metastasis (搜索) treatment.